1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novartis Looks To Lead CAR-T Expansion Into Autoimmune Disease

 
• By Andrew McConaghie

Novartis pioneered CAR-Ts for leukemia and lymphoma, and inspired by pioneering physician Georg Schett, it also hopes to be first in the race to revolutionize autoimmune disease treatment with the therapies, and has unveiled the first clinical data for its candidate.  

Novartis

CAR-Ts have revolutionized treatment of blood cancer over the last decade, but early academic data suggest they could now transform the lives of people living with severe autoimmune diseases.

Results from an academic study published in Nature Medicine in September 2022 showed CD19-targeted CAR-T therapy produced astonishing results in five patients with severe refractory systemic lupus erythematosus (srSLE), freeing them of all signs of the disease

Key Takeaways

  • Georg Schett’s groundbreaking work has sparked a race to develop CAR-Ts for autoimmune diseases

  • Novartis was the first company to launch a CD19 CAR-T in leukemia and lymphoma, and wants to be first in SLE too

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.